GlassScriptPhysician profile
Ardeshir Soroushyari
NPI 1487658811
$2,043.46
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,701 · 2020: $307 · 2022: $21.34 · 2024: $14.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $306.72 | 2019-2020 | |
| Amarin Pharma, INC. | $199.84 | 2019 | |
| Abbvie INC. | $193.83 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $161.72 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $141.54 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.46 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $135.93 | 2019-2020 | |
| Pfizer INC. | $133.88 | 2019 | |
| Radius Health, INC. | $124.75 | 2019 | |
| Sanofi-Aventis U.S. LLC | $81.53 | 2019 | |
| Allergan, INC. | $73.36 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.91 | 2019-2020 | |
| Dexcom, INC. | $67.20 | 2019-2022 | |
| Novo Nordisk INC | $57.34 | 2019-2020 | |
| Astellas Pharma US INC | $33.92 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $19.95 | 2019 | |
| Lilly USA, LLC | $18.46 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.03 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.07 | 2019 | |
| Gilead Sciences, INC. | $15.23 | 2019 | |
| Abbott Laboratories | $14.13 | 2024 | Freestyle Libre 3 |
| Antares Pharma, INC. | $12.42 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $10.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ardeshir Soroushyari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.